期刊
TRANSLATIONAL LUNG CANCER RESEARCH
卷 11, 期 12, 页码 2567-2587出版社
AME PUBLISHING COMPANY
DOI: 10.21037/tlcr-22-415
关键词
Lung carcinoid; diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH); bronchopulmonary; neuroendocrine
Pulmonary carcinoid tumors and DIPNECH are rare malignancies with multiple treatment options available, which should be sequenced according to the clinical status and disease biology. Discussion in a multidisciplinary setting and consideration of clinical trials are important for each patient.
Background and Objective: Low and intermediate grade neuroendocrine tumors of the lung are uncommon malignancies representing 2% of all lung cancers. These are termed typical and atypical pulmonary carcinoid tumors. These can arise in the setting of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH). The presentation, workup, management and outcomes of patients with these tumors can overlap with more common lung cancers but differ in that many of these patients have a prolonged clinical course. The objective of this narrative review is to summarize the literature and provide evidence and expert-based algorithms for work up and treatment of pulmonary carcinoids and DIPNECH.Methods: A search of PubMed and Web of Science databases ending April 15, 2022, with the following keywords lung carcinoid, DIPNECH, lung neuroendocrine, and bronchopulmonary carcinoid.Key Content and Findings: Pulmonary carcinoid tumors benefit from a multidisciplinary approach. Pre-treatment imaging with contrast-enhanced computed tomography, and DOTATATE positron emission tomography is required. Surgical resection is the gold standard for curative intent, and possibly including sublobar resections. Patients can recur or develop new primaries thus emphasizing the importance of surveillance; national guidelines recommend at least a 10-year follow up. A growing body of literature support the use of endobronchial therapy, with long responses documented. Systemic therapy consists of everolimus, somatostatin analogs, peptide receptor radionuclide therapy, and chemotherapy. Diffuse idiopathic pulmonary neuroendocrine tumor cell hyperplasia is rare, but series suggest somatostatin analogs may confer clinical benefit.Conclusions: Pulmonary carcinoid tumors and DIPNECH are rare. Despite lack of regulatory approvals for advanced disease, multiple options are available but should be sequenced according to the clinical status and disease biology. Each patient should be discussed in a multidisciplinary setting and clinical trials should be considered if available.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据